Lupin Limited, which had joined hands with Yoshindo Inc. in 2014 for a biosimilars joint venture in Japan, has chosen to go with another familiar face, the I’Rom Group, to develop and commercialize a denosumab biosimilar in the country.
While the Indian company didn’t specify reasons for the switch of partners in its anchor market for the APAC region, it follows a disclosure in its annual report that its
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?